CO6150123A2 - Formulacion de aerosol que contiene derivados de benzoxazin-3onas - Google Patents

Formulacion de aerosol que contiene derivados de benzoxazin-3onas

Info

Publication number
CO6150123A2
CO6150123A2 CO09028166A CO09028166A CO6150123A2 CO 6150123 A2 CO6150123 A2 CO 6150123A2 CO 09028166 A CO09028166 A CO 09028166A CO 09028166 A CO09028166 A CO 09028166A CO 6150123 A2 CO6150123 A2 CO 6150123A2
Authority
CO
Colombia
Prior art keywords
4alkyl
enantiomers
alkyl
halogen
formulation containing
Prior art date
Application number
CO09028166A
Other languages
English (en)
Inventor
Kirsten Radau
Michael Aven
Silvia Weitzel
Robin Yannik Weitzel
Vanessa Sabrina Weitzel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6150123A2 publication Critical patent/CO6150123A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- Formulación medicamentosa que contiene como principio activo uno o varios compuestos de la fórmula general 1en los queR1 significa hidrógeno, alquilo-C1-4, O-alquilo-C1-4 o halógeno; R2 significa hidrógeno, alquilo-C1-4, O-alquilo-C1-4 o halógeno; R3 significa hidrógeno, alquilo-C1-4, O-alquilo-C1-4-, halógeno, OH, -O-alquilen-C1-4-COOH u O-alquilen-C1-4-COO-alquilo-C1-4, X- significa un anión de carga negativa simple o múltiple, con preferencia un anión de carga negativa simple o múltiple seleccionado del grupo compuesto por cloruro, bromuro, yoduro, sulfato, fosfato, metansulfonato, nitrato, maleato, acetato, benzoato, citrato, salicilato, trifluoroacetato, fumarato, tartrato, oxalato, succinato, benzoato y p-toluensulfonato, eventualmente en forma de sus tautómeros, enantiómeros, mezclas de los enantiómeros, racematos, solvatos o hidratos; un principio activo 2 seleccionado del grupo consistente en budesonida, beclometasona, fluticasona, ciclesonida o un metabolito del mismo, eventualmente en forma de sus tautómeros, enantiómeros, mezclas de los enantiómeros, racematos, solvatos o hidratos; al menos un ácido farmacológicamente tolerable o un sistema tampón farmacológicamente tolerable, eventualmente otros coadyuvantes farmacológicamente tolerables, así como en calidad de disolvente agua, etanol o una mezcla de agua y etanol.
CO09028166A 2006-08-18 2009-03-18 Formulacion de aerosol que contiene derivados de benzoxazin-3onas CO6150123A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06119129 2006-08-18
EP07101128 2007-01-25

Publications (1)

Publication Number Publication Date
CO6150123A2 true CO6150123A2 (es) 2010-04-20

Family

ID=39082381

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09028166A CO6150123A2 (es) 2006-08-18 2009-03-18 Formulacion de aerosol que contiene derivados de benzoxazin-3onas

Country Status (17)

Country Link
US (1) US20080041370A1 (es)
EP (1) EP2054034A2 (es)
JP (1) JP2010501021A (es)
KR (1) KR20090040922A (es)
AR (1) AR062424A1 (es)
AU (1) AU2007285746A1 (es)
BR (1) BRPI0715692A2 (es)
CA (1) CA2660480A1 (es)
CO (1) CO6150123A2 (es)
EA (1) EA200900267A1 (es)
IL (1) IL197024A0 (es)
MX (1) MX2009001553A (es)
NO (1) NO20090410L (es)
PE (1) PE20080607A1 (es)
TW (1) TW200817010A (es)
UY (1) UY30543A1 (es)
WO (1) WO2008020056A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
ES2530991T3 (es) * 2005-08-15 2015-03-09 Boehringer Ingelheim Int Procedimiento para la obtención de betamiméticos
CN103796638A (zh) 2011-08-12 2014-05-14 勃林格殷格翰动物保健有限公司 遮味药物组合物
WO2014016548A2 (en) * 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
LT3473255T (lt) 2012-12-21 2022-03-10 Boehringer Ingelheim Vetmedica Gmbh Farmacinė vaisto forma, apimanti ciklezonidą
WO2014096115A1 (en) 2012-12-21 2014-06-26 Boehringer Ingelheim Vetmedica Gmbh Ciclesonide for the treatment of airway disease in horses
WO2014159251A2 (en) 2013-03-14 2014-10-02 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
PL3157522T3 (pl) 2014-06-18 2020-03-31 Boehringer Ingelheim Vetmedica Gmbh Antagonisty muskarynowi i ich kombinacje do leczenia choroby dróg oddechowych u koni
WO2017060386A1 (de) 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Verfahren zur beschichtung mikrostrukturierter bauteile
WO2021211858A1 (en) * 2020-04-16 2021-10-21 Anovent Pharmaceutical (U.S.), Llc Inhalable formulation of a solution containing tiotropium bromide and olodaterol
WO2021211850A1 (en) * 2020-04-16 2021-10-21 Anovent Pharmaceutical(U.S.)., Llc Inhalable formulation of a solution containing olodaterol
WO2021262648A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Preparation of a pharmaceutical composition of olodaterol and budesonide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
PL2422786T3 (pl) * 2004-04-22 2015-02-27 Boehringer Ingelheim Int Nowe kombinacje środków leczniczych do leczenia chorób dróg oddechowych
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten

Also Published As

Publication number Publication date
IL197024A0 (en) 2009-11-18
JP2010501021A (ja) 2010-01-14
US20080041370A1 (en) 2008-02-21
AR062424A1 (es) 2008-11-05
EP2054034A2 (de) 2009-05-06
CA2660480A1 (en) 2008-02-21
WO2008020056A3 (de) 2008-09-12
MX2009001553A (es) 2009-04-17
PE20080607A1 (es) 2008-07-17
TW200817010A (en) 2008-04-16
WO2008020056A2 (de) 2008-02-21
EA200900267A1 (ru) 2009-08-28
BRPI0715692A2 (pt) 2013-08-06
KR20090040922A (ko) 2009-04-27
AU2007285746A1 (en) 2008-02-21
UY30543A1 (es) 2008-03-31
NO20090410L (no) 2009-03-02

Similar Documents

Publication Publication Date Title
CO6150123A2 (es) Formulacion de aerosol que contiene derivados de benzoxazin-3onas
CO6170341A2 (es) Formulacion de aerosol que contiene derivados de benzoxazin-3onas
AR058082A1 (es) Formulacion en aerosol para la inhalacion de beta- agonistas
AR049096A1 (es) Formulacion en aerosol sin gas propelente para la inhalacion de beta-agonistas
NO20061833L (no) Aerosolformulgering for inhalering, inneholdende anticholinergt middel
AR124662A2 (es) Formulaciones inmunosupresoras
AR070936A1 (es) 1,2,4 -triazoles trisustituidos
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
MX2023006047A (es) Degradadores selectivos del receptor de estrogeno.
MY150519A (en) Imidazoquinolines with immuno-modulating properties
MX2012002011A (es) Composicion farmaceutica que contiene derivado de quinolina.
MX2009013626A (es) DERIVADO DE 17ß-CIANO-18A-HOMO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE.
EP1714961A4 (en) INDAZOL COMPOUND AND THEIR PHARMACEUTICAL USE
BR112012013511A2 (pt) derivados de difenil-pirazolopiridinas, sua preparação e seu uso como não moduladores do receptor nuclear
NO20070173L (no) Nye forbindelser
NO20080033L (no) Kinolinderivater som NK3-antagonister
BR112020008531A2 (pt) compostos antibacterianos
AR072802A1 (es) Derivados piperidinicos de esteres de acido bifenil-2-il-carbamico, antagonistas de receptores muscarinicos m3, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de trastornos digestivos,respiratorios y/o urinarios.
AR039935A1 (es) Formulacion farmaceutica de liberacion inmediata
AR075235A1 (es) Derivados de indol como agentes anticancer.
AR062477A1 (es) Formulacion aerosol para la inhalacion de beta - agonistas
AR065872A1 (es) Derivados de benzimidazol sustituidos con heterociclos,composiciones farmaceuticas que los contienen,proceso para prepararlos y sus usos en trastornos de ansiedad, trastornos depresivos y enfermedades de alzheimer, entre otros.
WO2008151746A3 (de) 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVAT, DESSEN VERWENDUNG UND DAS DERIVAT ENTHALTENDE ARZNEIMITTEL
AR081965A1 (es) Derivados aminoester de alcaloides y composicion medicinal de los mismos